 Disposition acid olsalazine mesalazine preparations patients ulcerative colitis comparison intraluminal colonic concentrations serum values urinary excretion disposition acid acetylated metabolite treatment olsalazine mesalazine patients inactive ulcerative colitis mesalazines Asacol mg Pentasa mg Salofalk mg crossover design trial drug days Intraluminal colonic concentrations days method equilibrium vivo dialysis faeces predose serum sample hour urine collection day acid values high performance liquid chromatography Olsalazine colonic concentrations mean SEM mmol/l active ingredient equimolar doses Pentasa mmol/l Salofalk mmol/l time olsalazine treatment serum concentrations urinary excretions mesalazine preparations low systemic load olsalazine reduces potential risk nephrotoxicity long term treatment